Boston, MA 04\/03\/2014 (wallstreetpr) –\u00a0Response Genetics, Inc. (NASDAQ:RGDX)<\/b> reported to sign contracts with 6 additional healthcare plans across 10 states with which it raised its total contracted membership to around 174 million lives.<\/p>\n
New Agreements<\/b><\/p>\n
Headquartered in Los Angeles, California, Response Genetics, Inc. (NASDAQ:RGDX) focuses on developing and selling diagnostics tests that determine a patient\u2019s response to cancer treatments. The company\u2019s new agreements include more Blue Cross Blue Shield deals in West Virginia, Delaware, Pennsylvania, South Dakota, Iowa and Arizona. It has also signed deals with Commercial Health Plan and Independent Physician Association in the North East and North West regions of the U.S. respectively. Each of these deals covers two states in their respective regions.<\/p>\n
With its new partnerships, Response Genetics has moved a step closer to its surging managed care program. The company\u2019s network now encompasses as many as 13 Blue Cross Blue Shield heathcare plans. This increases the total number of membership subscribers which have direct access to the company to around 23 million. Some of the contracts under the contracts are Blue Shield of California, CareFirst BlueCross BlueShield and Blue Cross and Blue Shield of Illinois.<\/p>\n
Benefits<\/b><\/p>\n
Apart from its recently introduced proprietary diagnostic test ResponseDX: Tissue of Origin (TM), the company\u2019s testing, whose lab is CLIA certified, is focusing mainly on selecting therapy for patients having lung, thyroid, melanoma, gastric and colon cancers. Response Genetics\u2019 series of assays on genomic treatments allows treating physicians to gain actionable data on the tumor of individual patients by predicting the best suited therapy for patients. The company\u2019s technologies assist in extracting and analyzing genetic information which are derived from these tumor cells which are stored in the form of specimens of paraffin-embedded and formalin-fixed variety. Hence, the participation of Response Genetics, Inc. (NASDAQ:RGDX) with the Blues strategies is expected to enhance plan members\u2019 access to custom tailored medical treatments for individual patients.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 04\/03\/2014 (wallstreetpr) –\u00a0Response Genetics, Inc. (NASDAQ:RGDX) reported to sign contracts with 6 additional healthcare plans across 10 states with which it raised its […]<\/p>\n","protected":false},"author":2,"featured_media":18609,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2835,2834],"stock_ticker":[],"class_list":["post-18606","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqrgdx","tag-response-genetics-inc-nasdaqrgdx","entry"],"acf":[],"yoast_head":"\n